DK2081562T3 - Method of administering volatile anesthetics for regional anesthesia and / or pain relief - Google Patents
Method of administering volatile anesthetics for regional anesthesia and / or pain relief Download PDFInfo
- Publication number
- DK2081562T3 DK2081562T3 DK07842927.1T DK07842927T DK2081562T3 DK 2081562 T3 DK2081562 T3 DK 2081562T3 DK 07842927 T DK07842927 T DK 07842927T DK 2081562 T3 DK2081562 T3 DK 2081562T3
- Authority
- DK
- Denmark
- Prior art keywords
- anesthetic
- pain
- solution
- use according
- subject
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims description 77
- 230000036407 pain Effects 0.000 title claims description 61
- 238000000034 method Methods 0.000 title claims description 41
- 239000003193 general anesthetic agent Substances 0.000 title description 27
- 229940035674 anesthetics Drugs 0.000 title description 17
- 238000002694 regional anesthesia Methods 0.000 title description 13
- 230000003444 anaesthetic effect Effects 0.000 claims description 103
- 239000000243 solution Substances 0.000 claims description 68
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 claims description 57
- 229960002725 isoflurane Drugs 0.000 claims description 56
- 150000002170 ethers Chemical class 0.000 claims description 33
- 210000005036 nerve Anatomy 0.000 claims description 16
- 239000013543 active substance Substances 0.000 claims description 15
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 claims description 15
- 230000009467 reduction Effects 0.000 claims description 13
- 229960002078 sevoflurane Drugs 0.000 claims description 13
- 238000001356 surgical procedure Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 208000000094 Chronic Pain Diseases 0.000 claims description 11
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 claims description 11
- 229960003132 halothane Drugs 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- 230000037324 pain perception Effects 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 208000005298 acute pain Diseases 0.000 claims description 5
- 239000002960 lipid emulsion Substances 0.000 claims description 5
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 claims description 5
- 229960002455 methoxyflurane Drugs 0.000 claims description 5
- DPYMFVXJLLWWEU-UHFFFAOYSA-N desflurane Chemical compound FC(F)OC(F)C(F)(F)F DPYMFVXJLLWWEU-UHFFFAOYSA-N 0.000 claims description 4
- 229960003537 desflurane Drugs 0.000 claims description 4
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 claims description 4
- 229960000305 enflurane Drugs 0.000 claims description 4
- 230000000737 periodic effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 241000700159 Rattus Species 0.000 description 27
- 206010002091 Anaesthesia Diseases 0.000 description 19
- 230000037005 anaesthesia Effects 0.000 description 19
- 230000036592 analgesia Effects 0.000 description 18
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 14
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 13
- 239000007789 gas Substances 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 238000002695 general anesthesia Methods 0.000 description 12
- 238000001802 infusion Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000003983 inhalation anesthetic agent Substances 0.000 description 9
- 210000002683 foot Anatomy 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 238000007726 management method Methods 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 6
- 238000002690 local anesthesia Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 238000001949 anaesthesia Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000003994 anesthetic gas Substances 0.000 description 3
- 238000009227 behaviour therapy Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940005483 opioid analgesics Drugs 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- -1 halogenated ether compound Chemical class 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000004237 neck muscle Anatomy 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 229910052724 xenon Inorganic materials 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000000003 Breakthrough pain Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000006298 dechlorination reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000002692 epidural anesthesia Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000036749 excitatory postsynaptic potential Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 230000008052 pain pathway Effects 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical class CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 231100000873 signs of neurotoxicity Toxicity 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84629306P | 2006-09-20 | 2006-09-20 | |
| US94721907P | 2007-06-29 | 2007-06-29 | |
| PCT/US2007/079097 WO2008036858A2 (en) | 2006-09-20 | 2007-09-20 | Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2081562T3 true DK2081562T3 (en) | 2016-05-30 |
Family
ID=39092912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07842927.1T DK2081562T3 (en) | 2006-09-20 | 2007-09-20 | Method of administering volatile anesthetics for regional anesthesia and / or pain relief |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20080119820A1 (https=) |
| EP (1) | EP2081562B1 (https=) |
| JP (4) | JP2010504359A (https=) |
| AU (1) | AU2007299738B2 (https=) |
| CA (1) | CA2663857C (https=) |
| DK (1) | DK2081562T3 (https=) |
| ES (1) | ES2573253T3 (https=) |
| PL (1) | PL2081562T3 (https=) |
| WO (1) | WO2008036858A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2721701B2 (ja) | 1989-04-20 | 1998-03-04 | 株式会社千代田製作所 | 有機溶剤を使用する洗浄装置の運転方法 |
| AU2015200210B2 (en) * | 2008-01-22 | 2016-08-11 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
| PL2244737T3 (pl) | 2008-01-22 | 2020-05-18 | The Board Of Regents Of The University Of Texas System | Kompozycje lotnego środka znieczulającego zawierające rozpuszczalniki ekstrakcyjne do znieczulania miejscowego i / albo zwalczania bólu |
| EP2244783B1 (en) | 2008-01-22 | 2019-12-18 | Board Of Regents, The University Of Texas System | Volatile anesthetic compositions and methods of use |
| WO2010025505A1 (en) * | 2008-09-04 | 2010-03-11 | Phebra Pty Ltd | Analgesia by transmucosal administration |
| CN109394689A (zh) | 2009-05-05 | 2019-03-01 | 德州大学系统董事会 | 挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法 |
| DE102010042615A1 (de) * | 2010-10-19 | 2012-04-19 | Wacker Chemie Ag | 1:1, 2:1- oder 3:1-Komplex bestehend aus einem Cyclodextrin oder Cyclodextrinderivat und einem halogeniertem Ether, seine Herstellung und seine Verwendung als Schlafmittel |
| EP2723325A4 (en) | 2011-06-24 | 2015-03-11 | Vapogenix Inc | NEW FORMULATIONS AND METHODS FOR TREATING DERMATOLOGICAL DISORDERS OR DISEASES |
| PL2968214T3 (pl) | 2013-03-15 | 2021-11-02 | Newvapogen, Inc. | Nowe kompozycje przeciwbólowe |
| US20150321770A1 (en) * | 2014-03-09 | 2015-11-12 | Davy Zide Qian | New method to prevent or stop an airplane from being hijacked and to minimize the effect of damage by using remote and wireless real-time monitoring and inhalational general anesthetic gases controlled from the ground (level) |
| CN104841025B (zh) * | 2015-04-16 | 2017-10-24 | 河南科技大学第一附属医院 | 一种用于密闭腰椎穿刺及脑脊液置换的装置 |
| WO2017011865A1 (en) | 2015-07-20 | 2017-01-26 | Medical Developments International Limited | Inhaler device for inhalable liquids |
| WO2017011867A1 (en) | 2015-07-20 | 2017-01-26 | Medical Developments International Limited | Inhaler device for inhalable liquids |
| EP3325062A4 (en) | 2015-07-20 | 2019-03-13 | Medical Developments International Limited | INHALER FOR INHALABLE LIQUIDS |
| AU2017325107B2 (en) | 2016-09-06 | 2022-10-06 | Medical Developments International Limited | Inhaler device for inhalable liquids |
| CN110141508A (zh) * | 2019-05-20 | 2019-08-20 | 崔文馨 | 无菌净化空气生理盐水 |
| EP4522112A1 (en) | 2022-05-13 | 2025-03-19 | Laboratorios Gebro Pharma, S.A. | Pharmaceutical composition for topical administration comprising a volatile anaesthetic |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE786675A (fr) * | 1971-08-02 | 1973-01-25 | Airco Inc | Separation d'oxydes d'alkyle halogenes par distillation azeotropique. |
| US4109651A (en) * | 1975-11-19 | 1978-08-29 | Steigerwald Allan M | Anesthetic gas exhaust system |
| US4453951A (en) * | 1980-07-09 | 1984-06-12 | General Electric Co. | Process for the production of silicone carbide composite |
| SE8008962L (sv) * | 1980-12-18 | 1982-06-19 | Erik Allan Lindkvist | Anordning vid narkosmask |
| US4879062A (en) | 1981-10-20 | 1989-11-07 | Adamantech, Inc. | Preparation of a gel having gas transporting capability |
| US4622219A (en) * | 1983-06-17 | 1986-11-11 | Haynes Duncan H | Method of inducing local anesthesia using microdroplets of a general anesthetic |
| US4744989A (en) | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| US5227165A (en) * | 1989-11-13 | 1993-07-13 | Nova Pharmaceutical Corporation | Liposphere delivery systems for local anesthetics |
| US5679650A (en) * | 1993-11-24 | 1997-10-21 | Fukunaga; Atsuo F. | Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine |
| US5677290A (en) * | 1990-05-10 | 1997-10-14 | Fukunaga; Atsuo F. | Therapeutic use of adenosine compounds as surgical anesthetics |
| US5114714A (en) * | 1990-11-29 | 1992-05-19 | Sepracor, Inc. | Methods of use and compositions of (r)-isoflurane and (r)-desflurane |
| US5114715A (en) * | 1990-11-29 | 1992-05-19 | Sepracor Inc. | Methods of use and compositions of (s)-isoflurane and (s)-desflurane |
| DE4105972C2 (de) * | 1991-02-26 | 1999-06-02 | Draegerwerk Ag | Narkosemitteldosiervorrichtung |
| GB9202238D0 (en) * | 1992-02-03 | 1992-03-18 | Wellcome Found | Compounds |
| US5230778A (en) * | 1992-05-01 | 1993-07-27 | Gavlin Associates | Purification of isoflurane by extractive distillation |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| GB9308306D0 (en) * | 1993-04-22 | 1993-06-09 | Univ Aberdeen | Analgesic composition |
| PT711289E (pt) * | 1993-07-30 | 2001-02-28 | Delta Pharmaceuticals Inc | Compostos piperazina utilizados em terapia |
| GB9423542D0 (en) | 1994-11-22 | 1995-01-11 | Marples Brian A | Pharmaceutical compounds |
| US5568910A (en) * | 1995-03-02 | 1996-10-29 | Delmarva Laboratories, Inc. | Anesthesia machine |
| US6248788B1 (en) * | 1996-11-06 | 2001-06-19 | The Regents Of The University Of California | Therapeutic method with capsaicin and capasicin analogs |
| US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
| US5919826A (en) | 1996-10-24 | 1999-07-06 | Algos Pharmaceutical Corporation | Method of alleviating pain |
| US20030212123A1 (en) * | 1997-05-05 | 2003-11-13 | Pfizer Inc. | COX-2 selective carprofen for treating pain and inflammation in dogs |
| CA2288828A1 (en) | 1997-07-14 | 1999-01-28 | Adolor Corporation | Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith |
| US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| US5976072A (en) * | 1998-01-29 | 1999-11-02 | Johns Hopkins University | Copa method for fiberoptic endotracheal intubation |
| AR015744A1 (es) | 1998-04-01 | 2001-05-16 | Orion Corp | Uso de dexmedetomidina para sedacion en terapia intensiva |
| US6830581B2 (en) * | 1999-02-09 | 2004-12-14 | Innercool Therspies, Inc. | Method and device for patient temperature control employing optimized rewarming |
| US6869440B2 (en) * | 1999-02-09 | 2005-03-22 | Innercool Therapies, Inc. | Method and apparatus for patient temperature control employing administration of anti-shivering agents |
| GB2350297A (en) | 1999-05-27 | 2000-11-29 | Abbott Lab | Injectable halogenated anesthetic formulation in emulsion form |
| US6653354B2 (en) * | 1999-07-29 | 2003-11-25 | Protexeon Limited | NMDA antagonist comprising xenon |
| US6706034B1 (en) * | 1999-12-30 | 2004-03-16 | Advanced Cardiovascular Systems, Inc. | Process for agent retention in biological tissues |
| US6669954B2 (en) * | 2000-01-25 | 2003-12-30 | John R. Crison | Controlled release of drugs |
| US20010036943A1 (en) * | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| AU2001254625B2 (en) | 2000-05-02 | 2006-02-02 | Action Pharma A/S | Use of alpha-MSH and EPO for preventing or treating ischemic conditions |
| US6770636B2 (en) * | 2000-08-18 | 2004-08-03 | Boehringer Ingelheim Pharma Kg | Phenyl-and phenylalkyl-substituted ethanolamines and ethylenediamines |
| AU2002256359A1 (en) | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Antisense and anti-inflammatory based compositions to treat respiratory disorders |
| US7758890B2 (en) * | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| MXPA04006572A (es) | 2002-01-10 | 2005-11-04 | Upjohn Co | Terapia de combinacion antivirica. |
| US20030181426A1 (en) * | 2002-02-11 | 2003-09-25 | Eisenach James C. | Compositions and methods for treating pain using cyclooxygenase-1 inhibitors |
| AU2003219167A1 (en) | 2002-03-19 | 2003-09-29 | Genset Sa | Treatment of metabolic disorders with a tnf receptor family member (fradj and/or cryptic) agonists or antagonists |
| ES2346868T3 (es) | 2002-08-10 | 2010-10-21 | Yale University | Antagonistas de receptor nogo. |
| CA2500310C (en) * | 2002-10-11 | 2013-03-12 | Baxter International, Inc. | Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics |
| NZ542690A (en) | 2003-03-28 | 2009-04-30 | Acadia Pharm Inc | Muscarinic M1 receptor agonists for pain management |
| WO2004100868A2 (en) | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
| US20030173287A1 (en) * | 2003-05-06 | 2003-09-18 | Johnston Arthur W | Filter devices and methods of use |
| EP1631234B1 (en) | 2003-05-16 | 2011-09-14 | Acorda Therapeutics, Inc. | Compositions and methods for the treatment of cns injuries |
| BRPI0413426A (pt) | 2003-08-07 | 2006-10-17 | Biogen Idec Inc | antagonistas de receptor novo |
| ATE395052T1 (de) | 2003-08-15 | 2008-05-15 | Ab Science | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes |
| DE602004015142D1 (de) | 2003-08-29 | 2008-08-28 | Childrens Medical Center | Antiangiogene peptide zur behandlung oder vorbeugung von endometriose |
| KR20060088885A (ko) | 2003-09-25 | 2006-08-07 | 아카디아 파마슈티칼스 인코포레이티드 | 뉴로펩티드 ｆｆ 리셉터 2의 작용제를 이용한 신경병증성통증 치료 방법 |
| US8557861B2 (en) | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
| TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| US20060198891A1 (en) | 2004-11-29 | 2006-09-07 | Francois Ravenelle | Solid formulations of liquid biologically active agents |
| WO2006064886A1 (ja) | 2004-12-16 | 2006-06-22 | Anges Mg, Inc. | 骨形成調節剤 |
| WO2006088088A1 (ja) | 2005-02-16 | 2006-08-24 | Astellas Pharma Inc. | Ｒｏｃｋ阻害剤を含有する疼痛治療剤 |
| EP2099408B1 (en) | 2006-11-28 | 2016-10-05 | Wisconsin Alumni Research Foundation | Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics |
| PL2244737T3 (pl) | 2008-01-22 | 2020-05-18 | The Board Of Regents Of The University Of Texas System | Kompozycje lotnego środka znieczulającego zawierające rozpuszczalniki ekstrakcyjne do znieczulania miejscowego i / albo zwalczania bólu |
| EP2244783B1 (en) | 2008-01-22 | 2019-12-18 | Board Of Regents, The University Of Texas System | Volatile anesthetic compositions and methods of use |
| CN109394689A (zh) | 2009-05-05 | 2019-03-01 | 德州大学系统董事会 | 挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法 |
-
2007
- 2007-09-20 CA CA2663857A patent/CA2663857C/en not_active Expired - Fee Related
- 2007-09-20 AU AU2007299738A patent/AU2007299738B2/en not_active Ceased
- 2007-09-20 EP EP07842927.1A patent/EP2081562B1/en active Active
- 2007-09-20 DK DK07842927.1T patent/DK2081562T3/en active
- 2007-09-20 US US11/858,497 patent/US20080119820A1/en not_active Abandoned
- 2007-09-20 WO PCT/US2007/079097 patent/WO2008036858A2/en not_active Ceased
- 2007-09-20 PL PL07842927T patent/PL2081562T3/pl unknown
- 2007-09-20 ES ES07842927.1T patent/ES2573253T3/es active Active
- 2007-09-20 JP JP2009529406A patent/JP2010504359A/ja active Pending
-
2011
- 2011-07-14 US US13/183,257 patent/US10357464B2/en active Active
-
2013
- 2013-10-09 JP JP2013211544A patent/JP5827658B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-16 JP JP2015204185A patent/JP6312146B2/ja not_active Expired - Fee Related
-
2017
- 2017-09-07 JP JP2017171713A patent/JP2017218450A/ja not_active Withdrawn
-
2019
- 2019-06-07 US US16/434,541 patent/US10799466B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US10357464B2 (en) | 2019-07-23 |
| ES2573253T3 (es) | 2016-06-06 |
| JP5827658B2 (ja) | 2015-12-02 |
| EP2081562A2 (en) | 2009-07-29 |
| JP2016041721A (ja) | 2016-03-31 |
| JP2014074028A (ja) | 2014-04-24 |
| AU2007299738B2 (en) | 2013-03-28 |
| US20190358173A1 (en) | 2019-11-28 |
| CA2663857C (en) | 2017-10-31 |
| US20080119820A1 (en) | 2008-05-22 |
| JP6312146B2 (ja) | 2018-04-18 |
| EP2081562B1 (en) | 2016-02-24 |
| JP2010504359A (ja) | 2010-02-12 |
| CA2663857A1 (en) | 2008-03-27 |
| WO2008036858A3 (en) | 2008-08-07 |
| AU2007299738A1 (en) | 2008-03-27 |
| US10799466B2 (en) | 2020-10-13 |
| JP2017218450A (ja) | 2017-12-14 |
| WO2008036858A2 (en) | 2008-03-27 |
| US20110269843A1 (en) | 2011-11-03 |
| PL2081562T3 (pl) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10799466B2 (en) | Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief | |
| US9566251B2 (en) | Volatile anesthetic compositions and methods of use | |
| EP2244737B1 (en) | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief | |
| CN101522180A (zh) | 用于区域麻醉和/和疼痛缓解的递送挥发性麻醉剂的方法 | |
| AU2019201703B2 (en) | Volatile anesthetic compositions and methods of use | |
| AU2015200210B2 (en) | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |